Provided by Tiger Fintech (Singapore) Pte. Ltd.

Quoin Pharmaceuticals

5.67
+0.19143.49%
Post-market: 5.66-0.0100-0.18%18:03 EDT
Volume:79.31K
Turnover:460.32K
Market Cap:3.33M
PE:-0.08
High:6.23
Open:5.29
Low:5.27
Close:5.48
Loading ...

Company Profile

Company Name:
Quoin Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
4
Office Location:
42127 Pleasant Forest Court,Ashburn,Virginia,United States
Zip Code:
20148-7349
Fax:
- -
Introduction:
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. operates as a subsidiary of Skinvisible, Inc.

Directors

Name
Position
Michael Myers
Chairman of the Board and Chief Executive Officer
Denise Carter
Director and Chief Operating Officer
Dennis H. Langer
Director
James Culverwell
Director
Joseph Cooper
Director
Michael Sember
Director
Natalie Leong
Director

Shareholders

Name
Position
Michael Myers
Chairman of the Board and Chief Executive Officer
Denise Carter
Director and Chief Operating Officer
Gordon Dunn
Chief Financial Officer